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Uganda and the Current HIV Treatment Crisis – A Perspective
According to UNAIDS (the Joint United Nations
Programme on HIV/AIDS), 33.3 million people
worldwide are infected with HIV. Of these, 10 million
require treatment with anti-retroviral therapy (ART).1
Currently, it is estimated that for every 100 people
who receive treatment, there are 250 more people
who become infected daily. This past October, the
Global Fund to Fight AIDS, Tuberculosis and Malaria,
an organization that provides treatment to roughly
half of the world’s poor population, failed to meet its
minimum fundraising target of $13 million, which
is the minimum necessary to continue distributing
anti-retroviral drugs to patients that have already
started treatment.2 This failure only serves to force
us to recognize the reality that some HIV-positive
individuals will be fortunate enough to be treated
with life-extending medications and some will not.
Uganda provides a good example of the controversy
surrounding global HIV/AIDS care and ART in
resource-poor settings. During the 1990s, Uganda was
viewed as a model for HIV/AIDS research, prevention,
and public health education, and was one of the first
countries in Africa to see a dramatic decrease in
HIV prevalence. Now, Uganda is once again in the
global spotlight, but as an example of one of the first
countries in which clinics are routinely turning people
away from care.3
In order to better understand the medical and
public health principles of HIV/AIDS care and how
treatment decisions are being made in resource-poor
settings, I traveled to Uganda recently to complete a
month-long medical student clinical elective. I visited
Makerere University’s Infectious Disease Institute
(IDI) in Kampala, one of the country’s state-of-the-art
HIV research and treatment facilities. This was my
ninth trip to Uganda; the first was during the mid-

1990s, when HIV prevalence was around 15% and
coffin shops lined the roads out of the capital city.
Today, the HIV prevalence in Uganda is 5.7% and
Kampala has the chaotic, palpable energy inherent
in all cities undergoing tremendous development
and growth.4 According to 2009 data, the number of
Ugandans living with HIV in was 1 million, with only
11% receiving anti-retroviral treatment.5,6
A non-governmental organization (NGO), the IDI
was established in 2004. It focuses on strengthening
the care and treatment of HIV and related infectious
diseases for people living with HIV across Africa
by offering professional training for health workers,
conducting research on best practices related to
HIV in low resource settings, and advancing clinical
services that support the development of new models
of HIV/AIDS care. The IDI started at a time when
ART was becoming more widely available in countries
where there were not enough clinicians to implement
treatment programs.7
Approximately 9,000 people currently receive care
at the IDI clinic, and an additional 6,000 receive care
through outreach activities.7 These patients, who
often travel from great distances, wait for hours with
hundreds of other patients, many of them quite
sick, to be monitored during routine visits. Due to
sheer volume, physicians and providers at the IDI
see an average of 60 patients per day. Many patients
that receive care at IDI do not qualify for treatment
with ART based on their T-cell count. According to
the World Health Organization’s clinical guidelines,
patients with T-cell counts below 350 should receive
ART.8 However, in Uganda, like most resource-poor
countries that cannot afford to treat patients based
on this guideline, the T-cell count cut off is 250 for
initiation of ART. Financial circumstances are forcing

physicians to apply sub-optimal criteria of care for
patients, including denying medications to those who
actually do clinically qualify for treatment. During my
rotation, I watched clinicians turn away patients and
make the sometimes impossible decisions regarding
who should be treated and why. Importantly, these
funding shortages also force patients to watch loved
ones suffer and make the difficult decision to share
or sell medications, which can ultimately lead to
treatment resistance.
Although my clinical rotation at the IDI was, in part,
about learning how to provide appropriate medical
care to persons with HIV/AIDS in Uganda, it was
also about re-examining a country that I care deeply
about at this specific point in history. As always, I
am inspired and impressed by Uganda’s dedication
to extraordinary research in the field of HIV/AIDS.
It is a country that, through research and example,
continues to provide the scientific foundation for
HIV treatment in resource-poor settings. At the
same time, I am angry and deeply saddened that the
current level of global commitment to HIV/AIDS
prevents clinicians from successfully translating this
research into a model of clinical care that minimizes
suffering and emphasizes principles of health equity.
When I read about the Global Fund’s fundraising
failure, the faces of the many HIV-positive patients I
saw in Uganda flashed through my mind. What will
happen to them? The difficult reality is that, almost
thirty years into the global HIV/AIDS pandemic,
most of these patients with HIV, and those who will
become infected, will die without ever accessing lifesaving treatment. 
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